Ocular Hypertension – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Ocular Hypertension – Drugs In Development, 2024 report and make more profitable business decisions.
Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea, and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.
The Ocular Hypertension drugs in development market research report provide comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Ocular Hypertension | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 51 molecules, with 48 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Ocular Hypertension therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Ocular Hypertension pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Ocular Hypertension treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAngelini Pharma SpA
Betaliq Inc
Chong Kun Dang Pharmaceutical Corp.
D. Western Therapeutics Institute Inc
Future Medicine Co Ltd
Glaukos Corp
Guangzhou Runer Ophthalmic Biotechnology Co Ltd
Ikarovec Ltd
Industrial Technology Research Institute
Jenivision Inc
Kowa Co Ltd
Laboratoires Thea SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
MediPrint Ophthalmics Inc
NicOx SA
Noveome Biotherapeutics Inc
Ocular Therapeutix Inc
Ocumension Therapeutics Co Ltd
Otsuka Pharmaceutical Co Ltd
pH Pharma Co Ltd
Qlaris Bio Inc
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shenzhen Hornetcorn Bio-technology Company Ltd
Skye Bioscience Inc
Sun Pharmaceutical Industries Ltd
Sustained Nano Systems LLC
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
Theratocular Biotek Co Ltd
University of North Carolina at Chapel Hill
ViSci Ltd
Visiox Pharma LLC
Visus Therapeutics Inc
Viva Vision Biotech
Whitecap Biosciences LLC
Yale University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Ocular Hypertension reports